Characteristic | Second-line therapy | ||
---|---|---|---|
Total* | Abiraterone acetate plus prednisone | Cabazitaxel plus prednisone | |
Age | N = 149 | N = 100 | N = 44 |
Median (range), years | 72.6 (49.0–89.6) | 73.9 (50.9–89.6) | 69.7 (51.4–84.4) |
≥75 years, n (%) | 62 (41.6) | 47 (47.0) | 13 (29.5) |
Prostate-specific antigen | N = 147 | N = 99 | N = 43 |
Median (range), ng/ml | 60.0 (0.9–3846.0) | 42.8 (1.2–3222.0) | 74.6 (0.9–3846.0) |
Gleason score, n (%) | N = 139 | N = 92 | N = 41 |
Median (range) | 7 (4–10) | 7 (4–10) | 8 (6–10) |
≤6, n/N (%) | 27 (19.7) | 24 (26.1) | 2 (4.9) |
=7, n (%) | 47 (34.3) | 30 (32.6) | 17 (41.5) |
≥8, n/N (%) | 63 (46.0) | 38 (41.3) | 22 (53.7) |
ECOG performance status, n (%) | N = 122 | N = 79 | N = 40 |
0 | 31 (25.4) | 22 (27.8) | 7 (17.5) |
1 | 70 (57.4) | 46 (58.2) | 24 (60.9) |
2 | 20 (16.4) | 10 (12.7) | 9 (22.5) |
3 | 0 (0.0) | 0 (0.0) | 0 (0.0) |
4 | 1 (0.8) | 1 (1.3) | 0 (0.0) |
Disease location, n (%) | N = 150 | N = 100 | N = 44 |
Bone metastases | 119 (79.9) | 76 (76.0) | 40 (90.9) |
Visceral metastases | 35 (23.5) | 24 (24.0) | 9 (20.5) |
Main current comorbidities | N = 150 | N = 100 | N = 44 |
Hypertension | 80 (53.3) | 52 (52.0) | 26 (59.1) |
Any cardiovascular disorder | 22 (14.7) | 18 (18.0) | 3 (6.8) |
Diabetes mellitus | 26 (17.3) | 17 (17.0) | 8 (18.2) |
Anemia | N = 147 | N = 97 | N = 44 |
Yes, n (%) | 31 (21.1) | 16 (16.5) | 15 (34.1) |
LDH increased | N = 130 | N = 85 | N = 39 |
Yes, n (%) | 80 (61.5) | 45 (52.9) | 31 (79.5) |
Alkaline phosphatase increased | N = 140 | N = 93 | N = 41 |
Yes, n (%) | 58 (41.4) | 32 (34.4) | 24 (58.5) |